Table 2.
Ongoing trials of ICIs combinations in the metastatic OC.
| Clinicaltrials.gov Registration Number (Name) |
Phase | ICI Combinations (Drug Class) |
|---|---|---|
| NCT03508570 | I | Nivolumab + Ipilimumab |
| NCT03355976 | II | |
| NCT02834013 | II | |
| NCT03959761 | I–II | Nivolumab (IP) + Surgery plus HIPEC |
| NCT02737787 | I | Nivolumab + WT1 or NY-ESO-1 (vaccine) |
| NCT03522246 (ATHENA) | III | Nivolumab + Rucaparib (PARPi) |
| NCT02873962 | II | Nivolumab + Bevacizumab (anti-VEGF) ± Rucaparib |
| NCT04611126 | I–II | Nivolumab + Relatimab (anti-LAG-3) + Ipilimumab + ACT |
| NCT03100006 | IB-IIA | Nivolumab + Oregovomab (anti-Ca125) |
| NCT04620954 (ORION-02) | I–II | Nivolumab + Oregovomab + PLD + CBDCA |
| NCT03667716 | I | Nivolumab + COM701 (PVRIG inhibitor) |
| NCT04570839 | I–II | Nivolumab + COM701 + BMS-986207 (anti-TIGIT) |
| NCT04514484 | I | Nivolumab + Cabozantinib (TKI) |
| NCT02335918 | I–II | Nivolumab, Varlilumab (anti-CD27) |
| NCT02526017 | I | Nivolumab + Cabiralizumab (anti-CSF1R) |
| NCT02440425 | II | Pembrolizumab + Paclitaxel |
| NCT03029598 | I–II | Pembrolizumab + CBDCA |
| NCT04387227 | II | |
| NCT04575961 (PERCEPTION) | II | Pembrolizumab + Platinum-based CTx |
| NCT02766582 | II | Pembrolizumab + CBDCA + Paclitaxel |
| NCT02834975 | II | |
| NCT03410784 (MITO28MaNGOov4) | II | |
| NCT02520154 | II | |
| NCT03126812 | I–II | |
| NCT03539328 | II | Pembrolizumab + Gemcitabine or Paclitaxel or PLD vs. CTx |
| NCT02900560 | II | Pembrolizumab ± Azacitidine |
| NCT02901899 | II | Pembrolizumab + Guadecitabine |
| NCT03596281 (PEMBOV) | I | Pembrolizumab + Bevacizumab + PLD |
| NCT04417192 (OLAPem) | II | Pembrolizumab + Olaparib |
| NCT03740165 (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | III | CBDCA + Paclitaxel → Pembrolizumab + Olaparib vs. Pembrolizumab + PBO vs. PBO + Olaparib |
| NCT04519151 | II | Pembrolizumab + Lenvatinib |
| NCT03797326 (MK-7902-005/E7080-G000-224/LEAP-005) | II | |
| NCT04781088 | II | Pembrolizumab + Lenvatinib + Paclitaxel |
| NCT02606305 | I–II | Pembrolizumab + Mirvetuximab soravtansine (anti-FRα ADC) |
| NCT03734692 | I–II | Pembrolizumab + IP Rintatolimod (anti-TLR3) + Cisplatin |
| NCT03158935 (ACTIVATE) | Pembrolizumab + Cyclophosphamide + autologous TILs + IL-2 | |
| NCT03029403 | II | Pembrolizumab + DPX-Survivac (vaccine) + Cyclophosphamide |
| NCT03113487 | II | Pembrolizumab + p53 MVA (vaccine) |
| NCT04713514 (TEDOVA) | II | Pembrolizumab + OSE2101 vs. OSE2101 (multi-epitope vaccine) |
| NCT03558139 | I | Avelumab + Magrolimab (anti-CD47) |
| NCT04510584 | II | Atezolizumab + Bevacizumab |
| NCT02891824 (ATALANTE) | III | Atezolizumab + Bevacizumab + platinum-based Ctx vs. PBO + Bevacizumab + platinum-based Ctx |
| NCT03353831 | III | Atezolizumab + Bevacizumab + Ctx vs. Bevacizumab + Ctx |
| NCT02839707 | II–III | Atezolizumab + Bevacizumab + PLD |
| NCT02659384 | II | Atezolizumab + Bevacizumab ± acetylsalicylic acid |
| NCT03363867 (BEACON) | II | Atezolizumab + Bevacizumab + Cobimetinib |
| NCT03695380 | I | Atezolizumab + Cobimetinib (anti-MEK) + Niraparib |
| NCT03598270 (ANITA) | III | Atezolizumab + Platinum-based Ctx vs. platinum-based Ctx → Niraparib ± Atezolizumab maintenance |
| NCT02914470 (PROLOG) | I | Atezolizumab + CBDCA + Cyclophosphamide |
| NCT03206047 | I–II | Atezolizumab + Guadecitabine + CDX-1401 (vaccine) |
| NCT03073525 | II | Atezolizumab + Vigil (cancer cell therapy) |
| NCT01975831 | I | Durvalumab + Tremelimumab |
| NCT02953457 | II | |
| NCT03026062 | II | |
| NCT04644289 (WoO) | II | Durvalumab + Olaparib |
| NCT04742075 (DOVACC) | II | Durvalumab + Olaparib + UV-1 |
| NCT04015739 (BOLD) | II | Durvalumab + Olaparib + Bevacizumab |
| NCT03737643 (DUO-O) | III | Durvalumab + platinum-based Ctx + Bevazicumab vs. PBO + platinum-based Ctx + Bevacizumab → Durvalumab + Bevacizumab + Olaparib maintenance |
| NCT03699449 (AMBITION) | II | Durvalumab + Tremelimumab or Olaparib or Cediranib or Ctx |
| NCT02726997 (N-Dur) | I–II | Durvalumab + CBDCA + Paclitaxel |
| NCT03430518 | I | Durvalumab + Eribuline |
| NCT03085225 (TRAMUNE) | I | Durvalumab + Trabectedin |
| NCT02811497 (METADUR) | II | Durvalumab + Azacitidine |
| NCT02764333 | II | Durvalumab + TPIV200 (anti-FR vaccine) |
| NCT02725489 | II | Durvalumab + Vigil |
| NCT03267589 | II | Durvalumab + Tremelimumab + MEDI 9447 (anti-CD73 Ab) + MEDI 0562 (anti-OX40) |
| NCT04019288 | I–II | Durvalumab + AVB-S6-500 (Anti-AXL Fusion Protein) |
| NCT03277482 | I | Durvalumab + Tremelimumab + RT |
| NCT02571725 | II | Tremelimumab + Olaparib |
| NCT03602859 | III | Dostarlimab (anti-PD1) + Ctx vs. Ctx + Niraparib vs. Ctx + PBO |
ACT: adoptive cell therapy; ADC: antibody-drug conjugate; CBDCA: carboplatin; CD: cluster of differentiation; CSF1R: Colony-stimulating factor 1 receptor; FRα: folate receptor alpha; HIPEC: Hyperthermic intraperitoneal chemotherapy; IL-2: Interleukin-2; IP: intra-peritoneal; LAG-3: Lymphocyte-activation gene 3; MVA: Modified Vaccinia Virus Ankara; NY-ESO-1: New York Esophageal Squamous Cell Carcinoma-1; PBO: placebo; PLD: pegylated liposomal doxorubicin; PVRIG: poliovirus receptor-related immunoglobulin domain containing; RT: Radiation Therapy; TIGIT: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif; TIL: tumor-infiltrating lymphocytes; TKI: tyrosine-kinase inhibitor; TLR3: Toll-Like Receptor 3; VEGF: vascular-endothelial growth factor; WT1: Wilms tumor 1; →: followed by.